The Foresight Group is an assembly of learned and accomplished individuals whose
broad perspectives and keen insights are an asset to procuring resources, to defining
the focal areas of research, to facilitating the translation of basic science into
clinical utility, and to fostering education in the pharmacological sciences in
the academic and business realms as well as the community.
|
|
Anthony P. Adamis, MD
Vice President
Genentech
San Francisco, CA
|
|
Ben S. Stefanski, II
President,
Polish American Cultural Center
Board Member and Full Time Volunteer,
Pulaski Franciscan Community Development Corporation
|
|
|
John A. Salon, PhD.
Director of Science
Molecular Pharmacology
Amgen, Inc.
Thousand Oaks, CA
|
|
Dr. Paul E. DiCorleto
Sherwin-Page Chairman
Cleveland Clinic Lerner Research Institute
|
|
|
Visvha Dixit, Ph.D.,
Vice-President, Research
Early Discovery Research Department
Genentech, Inc.
Vishva Dixit, Ph.D.,
Vice-President, Research
|
|
John A. Flower, Ph.D.
President and Professor Emeritus
Cleveland State University
Cleveland, OH
|
|
|
Stephen K. Burley M.D., D.Phil., F.R.S.C.
Chief Scientific Officer and Senior Vice-President Research
SGX Pharmaceuticals, Inc.
San Diego, CA
|
|
Robert A. Copeland, Ph.D.
Vice President
Enzymology & Mechanistic Pharmacology GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceutical Company
|
|
|
Ferid Murad, M.D. Ph.D.,
Nobel Laureate
Professor & Director,
Institute of Molecular Medicine
The University of Texas Health Science Center at Houston
|
|
David C.
U'Prichard, Ph.D.
President,
Druid Consulting LLC
|
|
|
Thomas C. Hohman, Ph.D.,
V.P. Retina Development
Alcon Research Ltd.
Ft. Worth, Texas
|